Other languages EXOPHARM

Equities

EX1

AU0000030975

Market Closed - Australian S.E. Other stock markets 01:10:45 02/10/2023 BST			5-day change	1st Jan Change
0.0275 ^AUD	+10.00%		-.--%	-.--%

05-01	Tryp Therapeutics Inc. completed the acquisition of Exopharm Limited in a reverse merger transaction.	CI
02-26	Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tryp Therapeutics Inc. completed the acquisition of Exopharm Limited in a reverse merger transaction.	04-30
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26
Exopharm Limited Announces Ian Dixon's Employment as CEO Expects to End in Early Calendar Year 2024	11-27
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23
Exopharm Limited Announces Executive Changes	22/06/23
Exopharm Achieves Initial Success With Exosome Products; Shares Fall 21%	28/04/23
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022	26/02/23
Exopharm Limited Announces Board Changes	22/02/23
Exopharm Limited Announces Resignation of Elizabeth McGregor as Non-Executive Director	20/12/22
Sartorius BIA Separations and Exopharm Ltd Testing the Synergy of Exopharm's Patented LEAP Technology Together with Bia's Unique Cim (Convective Interaction Media) Monolith Chromatography for Improved Large- Scale Exosome Production and Commercialization	16/11/22
Exopharm Limited Will Commence LEAP Technology Transfer to AIRM under MSA	13/11/22
Exopharm Limited Announces Study Results Indicate Exosomes Safe for Clinical Pursuit	27/09/22
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2022	30/08/22
Exopharm Limited Auditor Raises 'Going Concern' Doubt	29/08/22
Exopharm Enters Loan Agreement for Early Access to R&D Tax Rebate	16/06/22
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2021	25/02/22
Exopharm, AIRM Enter Collaborative Services Agreement	31/01/22
Exopharm Limited Signs Master Collaborative Services Agreement with the Astellas Institute for Regenerative Medicine	30/01/22
Exopharm Gets US Patent for Drug Delivery Technology	22/12/21
Exopharm : Widens After-Tax Loss in FY21; Shares Jump 6%	30/08/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages EXOPHARM

Equities

EX1

AU0000030975

Other languages

Filters